0.365  -0.008 (-2.12%)		07-23 16:00
Open: 0.365 High: 0.365 Volume: 4,819,177		Pre. Close: 0.3729 Low: 0.365 Market Cap: 22(M)

Short term
Mid term
Targets	6-month :	0.43	1-year :	0.45
Resists	First :	0.37	Second :	0.38
Pivot price	0.36
Supports	First :	0.35	Second :	0.29
MAs	MA(5) :	0.36	MA(20) :	0.37
	MA(100) :	0.34	MA(250) :	0.52
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	35.2	D(3) :	35.2
RSI	RSI(14): 45.7
52-week	High :	2.25	Low :	0.22

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ELEV ] has closed above bottom band by 30.4%. Bollinger Bands are 81% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.37 - 0.37	0.37 - 0.37
Low:	0.36 - 0.36	0.36 - 0.36
Close:	0.36 - 0.37	0.37 - 0.37

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Wed, 23 Jul 2025
Elevation Oncology completes merger with Concentra Biosciences, delists from Nasdaq - Investing.com

Wed, 23 Jul 2025
Elevation Oncology Completes Merger with Concentra Biosciences - TipRanks

Mon, 09 Jun 2025
Elevation Oncology agrees to Concentra Biosciences buyout - Investing.com

Mon, 09 Jun 2025
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders - Business Wire

Mon, 09 Jun 2025
Fenwick Represents Elevation Oncology in Definitive Merger Agreement with Concentra Biosciences - fenwick.com

Mon, 09 Jun 2025
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	59 (M)
Shares Float	44 (M)
Held by Insiders	0.3 (%)
Held by Institutions	59.7 (%)
Shares Short	2,080 (K)
Shares Short P.Month	2,550 (K)

EPS	-0.82
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.79
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-29.9 %
Return on Equity (ttm)	-78.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.78
Qtrly Earnings Growth	0 %
Operating Cash Flow	-40 (M)
Levered Free Cash Flow	-22 (M)

PE Ratio	-0.46
PEG Ratio	0
Price to Book value	0.46
Price to Sales	0
Price to Cash Flow	-0.55

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.